FINNENCE ▪ THE WIRE FILE
THE WIRE · № 80884
SEC Filing■ Unclear/unknown
META filed 4 on 2026-10-14
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A bare Form 4 filing confirms an insider transaction occurred but reveals no buy/sell direction.
Routine SEC filing lacking directional insider detail
CATALYST TO WATCH
Full Form 4 disclosure of shares and price
MAIN RISK
Overinterpreting a routine filing as meaningful
FULL DISPATCH
META (CIK 0001564475) filed a 4 on 2026-10-14.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTMeta Platforms · META
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.